Ghrelin expression is associated with a favorable outcome in male breast cancer

Show full item record



Permalink

http://hdl.handle.net/10138/246859

Citation

Grönberg , M , Nilsson , C , Markholm , I , Hedenfalk , I , Blomqvist , C , Holmberg , L , Tiensuu Janson , E & Fjällskog , M-L 2018 , ' Ghrelin expression is associated with a favorable outcome in male breast cancer ' , Scientific Reports , vol. 8 , 13586 . https://doi.org/10.1038/s41598-018-31783-x

Title: Ghrelin expression is associated with a favorable outcome in male breast cancer
Author: Grönberg, Malin; Nilsson, Cecilia; Markholm, Ida; Hedenfalk, Ingrid; Blomqvist, Carl; Holmberg, Lars; Tiensuu Janson, Eva; Fjällskog, Marie-Louise
Contributor organization: Department of Oncology
Clinicum
University of Helsinki
HUS Comprehensive Cancer Center
Date: 2018-09-11
Language: eng
Number of pages: 10
Belongs to series: Scientific Reports
ISSN: 2045-2322
DOI: https://doi.org/10.1038/s41598-018-31783-x
URI: http://hdl.handle.net/10138/246859
Abstract: Ghrelin and obestatin are two gastrointestinal peptides, derived from a common precursor. Expression of both peptides have been found in breast cancer tissue and ghrelin has been associated with breast cancer development. Ghrelin expression is associated with longer survival in women diagnosed with invasive and node negative breast cancer. The clinical implications of the peptide expression in male breast cancer are unclear. The aim of this study was to investigate the role and potential clinical value of ghrelin and obestatin in male breast cancer. A tissue microarray of invasive male breast cancer specimens from 197 patients was immunostained with antibodies versus the two peptides. The expression of the peptides was correlated to previously known prognostic factors in breast cancer and to the outcome. No strong correlations were found between ghrelin or obestatin expression and other known prognostic factors. Only ghrelin expression was statistically significantly correlated to breast cancer-specific survival (HR 0.39, 95% CI 0.18-0.83) in univariate analyses and in multivariate models, adjusted for tumor size and node status (HR 0.38, 95% CI 0.17-0.87). HR for obestatin was 0.38 (95% CI 0.11-1.24). Ghrelin is a potential prognostic factor for breast cancer death in male breast cancer. Patients with tumors expressing ghrelin have a 2.5-fold lower risk for breast cancer death than those lacking ghrelin expression. Drugs targeting ghrelin are currently being investigated in clinical studies treating metabolic or nutritional disorders. Ghrelin should be further evaluated in forthcoming studies as a prognostic marker with the aim to be included in decision algorithms.
Subject: HORMONE-RELEASING-HORMONE
DES-ACYL GHRELIN
CELL-LINES
BIOLOGICAL-ACTIVITY
FOOD-INTAKE
OBESTATIN
PEPTIDE
GENE
RECEPTORS
CARCINOMA
3122 Cancers
3111 Biomedicine
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
s41598_018_31783_x.pdf 1.749Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record